CHO PHARMA, INC.
National Biotechnology Research Park (Resident company)
CHO PHARMA INC. was founded in 2013. As a pioneer in innovative glycotechnology and carbohydrate new drug development, we are devoted in providing better solutions for severe human diseases. Our core expertise is in the field of glycoengineering and the development of vaccine and antibody against novel carbohydrate antigens. Several pipeline products, which cover indications for human cancer, infection disease and autoimmune disease, have been created through our proprietary technologies CHOptimax™ and the integrated anti-carbohydrate vaccine and antibody development platform. CHO-H01, our first product for human non-Hodgkin lymphoma, has been approved to conduct phase I/II clinical trials in both Taiwan and the US. More product candidates are expected to be launched for clinical trials in the near future. Another product, universal COVID-19 vaccine, is a new vaccine also designed by CHOptimax™.